Qualigens Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 18-07-2024
- Paid Up Capital ₹ 1.55 Cr
as on 18-07-2024
- Company Age 11 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 37.99 Cr
as on 18-07-2024
- Revenue 45.61%
(FY 2023)
- Profit 26.63%
(FY 2023)
- Ebitda 37.14%
(FY 2023)
- Net Worth 35.31%
(FY 2023)
- Total Assets 25.08%
(FY 2023)
About Qualigens Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.55 Cr.
The company currently has active open charges totaling ₹37.99 Cr.
Ajit Jain, Aayush Jain, and Ankit Paharia serve as directors at the Company.
- CIN/LLPIN
U24100MH2013PTC249071
- Company No.
249071
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Oct 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Khalapur, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Qualigens Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajit Jain  | Director | 10-Mar-2016 | Current |
| Aayush Jain | Director | 01-Aug-2017 | Current |
| Ankit Paharia | Director | 10-Oct-2013 | Current |
Financial Performance and Corporate Structure Insights of Qualigens Pharma.
Qualigens Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 45.61% increase. The company also saw a substantial improvement in profitability, with a 26.63% increase in profit. The company's net worth Soared by an impressive increase of 35.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Qualigens Pharma?
In 2023, Qualigens Pharma had a promoter holding of 0.65% and a public holding of 99.34%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Jinendra Qualipharm Private LimitedActive 15 years 2 months
Ajit Jain and Aayush Jain are mutual person
- Bulwark Business Services LlpActive 4 years 9 months
Aayush Jain and Ankit Paharia are mutual person
- Ajaayu Trading And Consultancy Private LimitedActive 24 years 11 months
Aayush Jain is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 22 Apr 2021 | ₹11.00 Cr | Open |
Others Creation Date: 27 Feb 2020 | ₹2.24 Cr | Open |
Others Creation Date: 17 Jul 2019 | ₹24.75 Cr | Open |
How Many Employees Work at Qualigens Pharma?
Qualigens Pharma has a workforce of 226 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Qualigens Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Qualigens Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
